Gloria Ortiz, MD
Endocrinology, Diabetes & Metabolism · McAllen, TXNPI 1871825307
Payments from drug & device makers
Across 1,388 payments — averaging $1370.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$656K
- Bayer$309K
- Novo Nordisk$264K
- Senseonics, Incorporated$192K
- Rhythm Pharmaceuticals, Inc.$186K
- Lilly USA, LLC$80K
- plus $215K from 26 others
Across 2 payments — averaging $1819.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 13 | $656,463 |
| Bayer | 104 | $308,523 |
| Novo Nordisk | 419 | $264,284 |
| Senseonics, Incorporated | 118 | $191,756 |
| Rhythm Pharmaceuticals, Inc. | 212 | $185,974 |
| Lilly USA, LLC | 108 | $80,345 |
| Boehringer Ingelheim | 77 | $57,908 |
| Johnson & Johnson | 60 | $42,556 |
| Ascendis Pharma Endocrinology Inc | 85 | $37,844 |
| Sanofi-aventis U.S. LLC | 63 | $32,839 |
| Amgen | 22 | $22,674 |
| Xeris Pharmaceuticals, Inc. | 21 | $18,146 |
| Abbott | 13 | $443 |
| Medtronic(2 entities) | 6 | $402 |
| Dexcom, Inc. | 17 | $315 |
| Amarin Pharma, Inc. | 12 | $278 |
| AstraZeneca | 7 | $196 |
| Insulet Corporation | 11 | $185 |
| Corcept Therapeutics | 3 | $166 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Novartis | 1 | $137 |
| Intuitive Surgical | 1 | $129 |
| Janssen Scientific Affairs, LLC | 1 | $71 |
| Tempus AI, Inc | 1 | $66 |
| Sequel Med Tech, LLC | 2 | $46 |
| Intuity Medical Inc | 2 | $37 |
| Antares Pharma, Inc. | 2 | $33 |
| BETA Bionics, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Novo Nordisk AS | 2 | $4 |
How this compares
$1,902,045 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in McAllen
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.